<DOC>
	<DOCNO>NCT00279019</DOCNO>
	<brief_summary>GSK233705 high-affinity specific muscarinic receptor ( mAChR ) antagonist develop daily treatment chronic obstructive pulmonary disease ( COPD ) . The long duration action GSK233705 administer via inhalation animal model support potential use once-daily bronchodilator chronic obstructive pulmonary disease . GSK233705 high-affinity specific muscarinic receptor ( mAChR ) antagonist develop daily treatment chronic obstructive pulmonary disease ( COPD ) . The long duration action GSK233705 administer via inhalation animal model support potential use once-daily bronchodilator chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Of nonchildbearing potential . Diagnosed COPD , define GOLD guideline . Smoker exsmoker smoke history least 10 pack year . FEV1/FVC &lt; 0.7 postbronchodilator ( salbutamol ) . FEV1 &lt; = 80 % predict normal height , age gender inhalation salbutamol . Response ipratropium bromide 9 . Subject 's weight 60kg . Exclusion criterion : Past present disease , judge Investigator Medical Monitor , may affect outcome study . FEV1 &lt; =50 % predict inhalation salbutamol . Tested positive hepatitis C antibody , hepatitis B surface antigen HIV . Has claustrophobia may aggravate enter plethysmography cabinet . Has prostate hypertrophy narrow angle glaucoma . Diagnosis active tuberculosis , lung cancer , clinically overt bronchiectasis , allergic rhinitis , asthma . Poorly control COPD . Participated Pulmonary Rehabilitation Program within 4 week prior screen visit enter program study . Had respiratory tract infection 4 week prior screen visit throughout duration study . History congestive heart failure , coronary insufficiency cardiac arrhythmia . A mean QTc ( B ) value screen &gt; 440msec , QTc ( B ) 3 screen ECGs within 10 % mean , PR interval outside range 120210msec ECG suitable QT measurement . A history elevate supine blood pressure mean blood pressure equal high 160/95 mmHg . A mean heart rate outside range 4090 bpm . QTc prolongation &gt; 470msec risk factor torsades de pointes ( heart failure NYHA IIIV , hypokalaemia , familial long QT syndrome ) . Receiving comedication drug prolong QTc interval . Requires treatment inhale cromolyn sodium nedocromil , oral beta2agonists , nebulised beta2agonists , nebulised anticholinergic leukotriene modifier . Unable abstain xanthine ( caffeine . Unable abstain shortacting inhaled bronchodilator . Unable abstain longacting inhaled bronchodilator . Changed dose inhale oral corticosteroid within last 6 week . Taking 10mg/day prednisolone ( equivalent ) . Receiving treatment long term shortterm oxygen therapy require nocturnal positive pressure sleep apnea .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GSK233705</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>COPD</keyword>
</DOC>